Clinical trial NCT03869008 - References

Raynaud Phenomenon — Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.

Citation(s)

•   Brand FN, Larson MG, Kannel WB, McGuirk JM
  The occurrence of Raynaud's phenomenon in a general population: the Framingham Study. Vasc Med. 1997 Nov;2(4):296-301.
•   Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM
  Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001 Sep;40(9):1038-43.
•   Ennis H, Anderson ME, Wilkinson J, Herrick AL
  Calcium channel blockers for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2014 Jan 30;(1):CD002069. doi: 10.1002/14651858.CD002069.pub4. Review. Update in: Cochrane Database Syst Rev. 2016;2:CD002069.
•   Garner R, Kumari R, Lanyon P, Doherty M, Zhang W
  Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 2015 Mar 16;5(3):e006389. doi: 10.1136/bmjopen-2014-006389. Review.
•   James PB
  Cooling patterns in Raynaud's phenomenon and allied peripheral vascular disorders. Br J Surg. 1968 Nov;55(11):860.
•   Johnson RL, Wilson CG
  A review of vagus nerve stimulation as a therapeutic intervention. J Inflamm Res. 2018 May 16;11:203-213. doi: 10.2147/JIR.S163248. eCollection 2018. Review.
•   Matucci-Cerinic M, Kahaleh B, Wigley FM
  Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 2013 Aug;65(8):1953-62. doi: 10.1002/art.37988. Review.
•   Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM; Scleroderma Clinical Trials Consortium
  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 2002 Sep;46(9):2410-20.
•   Pauling JD, Shipley JA, Harris ND, McHugh NJ
  Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis. Clin Exp Rheumatol. 2012 Mar-Apr;30(2 Suppl 71):S103-15. Epub 2012 May 30. Review.
•   Pauling JD, Shipley JA, Raper S, Watson ML, Ward SG, Harris ND, McHugh NJ
  Comparison of infrared thermography and laser speckle contrast imaging for the dynamic assessment of digital microvascular function. Microvasc Res. 2012 Mar;83(2):162-7. doi: 10.1016/j.mvr.2011.06.012. Epub 2011 Jul 1.
•   Schlager O, Gschwandtner ME, Herberg K, Frohner T, Schillinger M, Koppensteiner R, Mlekusch W
  Correlation of infrared thermography and skin perfusion in Raynaud patients and in healthy controls. Microvasc Res. 2010 Jul;80(1):54-7. doi: 10.1016/j.mvr.2010.01.010. Epub 2010 Feb 6.
•   Silberstein SD, Calhoun AH, Treppendahl C, Dodick DW, Rapoport AM, Mamidi A, Vargas P, Ebert TH, Tepper SJ
  The emerging role of gammaCore® in the management of cluster headache: expert panel recommendations. Am J Manag Care. 2017 Nov;23(17 Suppl):S326-S333.
•   Zaproudina N, Varmavuo V, Airaksinen O, Närhi M
  Reproducibility of infrared thermography measurements in healthy individuals. Physiol Meas. 2008 Apr;29(4):515-24. doi: 10.1088/0967-3334/29/4/007. Epub 2008 Apr 9.

Potential Benefit for Non Invasive Vagus Nerve Stimulation (nVNS) Using GammaCore in the Treatment of Raynaud's Phenomena.

Details for clinical trial NCT03869008